Bolt Biotherapeutics, Inc. (BOLT)
Market Cap | 39.47M |
Revenue (ttm) | 6.78M |
Net Income (ttm) | -76.79M |
Shares Out | 37.95M |
EPS (ttm) | -2.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 280,628 |
Open | 1.10 |
Previous Close | 1.09 |
Day's Range | 1.02 - 1.12 |
52-Week Range | 1.01 - 2.03 |
Beta | 0.86 |
Analysts | Buy |
Price Target | 5.00 (+380.77%) |
Earnings Date | Nov 9, 2023 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-... [Read more]
Financial Performance
In 2022, BOLT's revenue was $5.73 million, an increase of 354.68% compared to the previous year's $1.26 million. Losses were -$88.10 million, -10.64% less than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 380.77% from the latest price.
News

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of can...

Bolt Biotherapeutics to Participate in September Investor Conferences
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
REDWOOD CITY, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
REDWOOD CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be prese...

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cance...

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of can...

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the tre...

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment...

Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

Bolt Biotherapeutics to Present at February Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of canc...

Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment ...

Bolt, Orion-E to build solar plants in Brazil for about $630 million
Energy infrastructure company Orion-E has reached an agreement with energy trader Bolt to build solar photovoltaic plants in Brazil with a combined capacity of 500 megawatts (MW), a company executive ...

Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy...

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present -

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
– BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine...

Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
REDWOOD CITY, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine...

Bolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidate
Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising...

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen

Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021
REDWOOD CITY, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine ...

Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the ta...